Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- AHPA Releases 2006-2007 Tonnage Survey Questionnaire
The American Herbal Products Association’s (AHPA) 2006-2007 Tonnage Survey Questionnaire is now available online.
- AHPA Releases 2006-2007 Tonnage Survey Questionnaire
The American Herbal Products Association’s (AHPA) 2006-2007 Tonnage Survey Questionnaire is now available online.
- AHPA Releases 2006-2007 Tonnage Survey Questionnaire
The American Herbal Products Association’s (AHPA) 2006-2007 Tonnage Survey Questionnaire is now available online.
- AHPA Releases 2006-2007 Tonnage Survey Questionnaire
The American Herbal Products Association’s (AHPA) 2006-2007 Tonnage Survey Questionnaire is now available online.
- AHPA Releases 2006-2007 Tonnage Survey Questionnaire
The American Herbal Products Association’s (AHPA) 2006-2007 Tonnage Survey Questionnaire is now available online.
- AHPA Releases 2006-2007 Tonnage Survey Questionnaire
The American Herbal Products Association’s (AHPA) 2006-2007 Tonnage Survey Questionnaire is now available online.
- AHPA Releases 2006-2007 Tonnage Survey Questionnaire
The American Herbal Products Association’s (AHPA) 2006-2007 Tonnage Survey Questionnaire is now available online.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Arterial Calcification Reduced With Vitamin K2 Intake According to New Study
PL Thomas and NattoPharma have announced that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Promising Results for Enzymotec's Sharp-PS™ Clinical Trial
Enzymotec has announced that treatment with Sharp-PSTM showed improved memory and attention parameters in test subjects who complained of memory problems.
- Open Nutrition Journal Reports EpiCor to Support Red Blood Cell Health, Mucosal Immune Protection
Embria(R) Health Sciences has announced that its supplement EpiCor(R) supports the formation of healthy red blood cells, supports and protects mucosal immune health and provides anti-inflammatory support, according to a study published in the most recent issue of the peer- reviewed publication, The Open Nutrition Journal.
- Open Nutrition Journal Reports EpiCor to Support Red Blood Cell Health, Mucosal Immune Protection
Embria(R) Health Sciences has announced that its supplement EpiCor(R) supports the formation of healthy red blood cells, supports and protects mucosal immune health and provides anti-inflammatory support, according to a study published in the most recent issue of the peer- reviewed publication, The Open Nutrition Journal.
- Open Nutrition Journal Reports EpiCor to Support Red Blood Cell Health, Mucosal Immune Protection
Embria(R) Health Sciences has announced that its supplement EpiCor(R) supports the formation of healthy red blood cells, supports and protects mucosal immune health and provides anti-inflammatory support, according to a study published in the most recent issue of the peer- reviewed publication, The Open Nutrition Journal.
- Open Nutrition Journal Reports EpiCor to Support Red Blood Cell Health, Mucosal Immune Protection
Embria(R) Health Sciences has announced that its supplement EpiCor(R) supports the formation of healthy red blood cells, supports and protects mucosal immune health and provides anti-inflammatory support, according to a study published in the most recent issue of the peer- reviewed publication, The Open Nutrition Journal.
- Open Nutrition Journal Reports EpiCor to Support Red Blood Cell Health, Mucosal Immune Protection
Embria(R) Health Sciences has announced that its supplement EpiCor(R) supports the formation of healthy red blood cells, supports and protects mucosal immune health and provides anti-inflammatory support, according to a study published in the most recent issue of the peer- reviewed publication, The Open Nutrition Journal.
- Open Nutrition Journal Reports EpiCor to Support Red Blood Cell Health, Mucosal Immune Protection
Embria(R) Health Sciences has announced that its supplement EpiCor(R) supports the formation of healthy red blood cells, supports and protects mucosal immune health and provides anti-inflammatory support, according to a study published in the most recent issue of the peer- reviewed publication, The Open Nutrition Journal.
- Open Nutrition Journal Reports EpiCor to Support Red Blood Cell Health, Mucosal Immune Protection
Embria(R) Health Sciences has announced that its supplement EpiCor(R) supports the formation of healthy red blood cells, supports and protects mucosal immune health and provides anti-inflammatory support, according to a study published in the most recent issue of the peer- reviewed publication, The Open Nutrition Journal.
- Arterial Calcification Reduced with Vitamin K2 Intake According to New Study in the Scientific Journal "Atherosclerosis"
Researchers of the University of Utrecht in The Netherlands examined 564 post-menopausal women regarding whether a daily intake of vitamin K1 and K2 is associated with the degree of coronary calcification. A higher intake of vitamin K2 was associated with 20% reduction of coronary calcification.
- Arterial Calcification Reduced with Vitamin K2 Intake According to New Study in the Scientific Journal "Atherosclerosis"
Researchers of the University of Utrecht in The Netherlands examined 564 post-menopausal women regarding whether a daily intake of vitamin K1 and K2 is associated with the degree of coronary calcification. A higher intake of vitamin K2 was associated with 20% reduction of coronary calcification.
- Vitamin D a Bone Booster for People with Digestive Problems
People with digestive diseases, such as ulcerative colitis and Crohn’s disease, are especially susceptible to osteoporosis and bone fractures, due in part to nutrient deficiencies caused by malabsorption and medication side effects. A new study found that people with good vitamin D status early in the course of their disease had higher bone density and a greater likelihood of increasing bone density over time.
- Vitamin D a Bone Booster for People with Digestive Problems
People with digestive diseases, such as ulcerative colitis and Crohn’s disease, are especially susceptible to osteoporosis and bone fractures, due in part to nutrient deficiencies caused by malabsorption and medication side effects. A new study found that people with good vitamin D status early in the course of their disease had higher bone density and a greater likelihood of increasing bone density over time.
- Vitamin D a Bone Booster for People with Digestive Problems
People with digestive diseases, such as ulcerative colitis and Crohn’s disease, are especially susceptible to osteoporosis and bone fractures, due in part to nutrient deficiencies caused by malabsorption and medication side effects. A new study found that people with good vitamin D status early in the course of their disease had higher bone density and a greater likelihood of increasing bone density over time.
- Vitamin D a Bone Booster for People with Digestive Problems
People with digestive diseases, such as ulcerative colitis and Crohn’s disease, are especially susceptible to osteoporosis and bone fractures, due in part to nutrient deficiencies caused by malabsorption and medication side effects. A new study found that people with good vitamin D status early in the course of their disease had higher bone density and a greater likelihood of increasing bone density over time.
- Vitamin D a Bone Booster for People with Digestive Problems
People with digestive diseases, such as ulcerative colitis and Crohn’s disease, are especially susceptible to osteoporosis and bone fractures, due in part to nutrient deficiencies caused by malabsorption and medication side effects. A new study found that people with good vitamin D status early in the course of their disease had higher bone density and a greater likelihood of increasing bone density over time.
- Vitamin D a Bone Booster for People with Digestive Problems
People with digestive diseases, such as ulcerative colitis and Crohn’s disease, are especially susceptible to osteoporosis and bone fractures, due in part to nutrient deficiencies caused by malabsorption and medication side effects. A new study found that people with good vitamin D status early in the course of their disease had higher bone density and a greater likelihood of increasing bone density over time.
- Vitamin D a Bone Booster for People with Digestive Problems
People with digestive diseases, such as ulcerative colitis and Crohn’s disease, are especially susceptible to osteoporosis and bone fractures, due in part to nutrient deficiencies caused by malabsorption and medication side effects. A new study found that people with good vitamin D status early in the course of their disease had higher bone density and a greater likelihood of increasing bone density over time.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- Nutrition 21 Reports that National Toxicology Program Studies Support the Safety of Chromium Picolinate
Nutrition 21, Inc., has reported that study results released by the National Toxicology Program (NTP) support the safety of short-term and long-term use of Chromium Picolinate. Multiple safety studies were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.
- SemBioSys Eligible to Proceed With Phase I/II Plant-produced Insulin Trial After Submission of IND
SemBioSys Genetics Inc., has announced that it is eligible to proceed with its planned Phase I/II human clinical trial of plant-produced insulin now that the 30-day review period of its Investigational New Drug (IND) application has passed. SemBioSys intends to conduct the Phase I/II insulin trial in Europe. Prior to proceeding with the planned trial in the United Kingdom, the company's Clinical Trial Application (CTA) must be reviewed by the appropriate European regulatory authorities.
- SemBioSys Eligible to Proceed With Phase I/II Plant-produced Insulin Trial After Submission of IND
SemBioSys Genetics Inc., has announced that it is eligible to proceed with its planned Phase I/II human clinical trial of plant-produced insulin now that the 30-day review period of its Investigational New Drug (IND) application has passed. SemBioSys intends to conduct the Phase I/II insulin trial in Europe. Prior to proceeding with the planned trial in the United Kingdom, the company's Clinical Trial Application (CTA) must be reviewed by the appropriate European regulatory authorities.
- SemBioSys Eligible to Proceed With Phase I/II Plant-produced Insulin Trial After Submission of IND
SemBioSys Genetics Inc., has announced that it is eligible to proceed with its planned Phase I/II human clinical trial of plant-produced insulin now that the 30-day review period of its Investigational New Drug (IND) application has passed. SemBioSys intends to conduct the Phase I/II insulin trial in Europe. Prior to proceeding with the planned trial in the United Kingdom, the company's Clinical Trial Application (CTA) must be reviewed by the appropriate European regulatory authorities.
- SemBioSys Eligible to Proceed With Phase I/II Plant-produced Insulin Trial After Submission of IND
SemBioSys Genetics Inc., has announced that it is eligible to proceed with its planned Phase I/II human clinical trial of plant-produced insulin now that the 30-day review period of its Investigational New Drug (IND) application has passed. SemBioSys intends to conduct the Phase I/II insulin trial in Europe. Prior to proceeding with the planned trial in the United Kingdom, the company's Clinical Trial Application (CTA) must be reviewed by the appropriate European regulatory authorities.
- SemBioSys Eligible to Proceed With Phase I/II Plant-produced Insulin Trial After Submission of IND
SemBioSys Genetics Inc., has announced that it is eligible to proceed with its planned Phase I/II human clinical trial of plant-produced insulin now that the 30-day review period of its Investigational New Drug (IND) application has passed. SemBioSys intends to conduct the Phase I/II insulin trial in Europe. Prior to proceeding with the planned trial in the United Kingdom, the company's Clinical Trial Application (CTA) must be reviewed by the appropriate European regulatory authorities.
- SemBioSys Eligible to Proceed With Phase I/II Plant-produced Insulin Trial After Submission of IND
SemBioSys Genetics Inc., has announced that it is eligible to proceed with its planned Phase I/II human clinical trial of plant-produced insulin now that the 30-day review period of its Investigational New Drug (IND) application has passed. SemBioSys intends to conduct the Phase I/II insulin trial in Europe. Prior to proceeding with the planned trial in the United Kingdom, the company's Clinical Trial Application (CTA) must be reviewed by the appropriate European regulatory authorities.
- SemBioSys Eligible to Proceed With Phase I/II Plant-produced Insulin Trial After Submission of IND
SemBioSys Genetics Inc., has announced that it is eligible to proceed with its planned Phase I/II human clinical trial of plant-produced insulin now that the 30-day review period of its Investigational New Drug (IND) application has passed. SemBioSys intends to conduct the Phase I/II insulin trial in Europe. Prior to proceeding with the planned trial in the United Kingdom, the company's Clinical Trial Application (CTA) must be reviewed by the appropriate European regulatory authorities.
- Survey Reveals Top Five Reasons Physicians Recommend Dietary Supplements to Their Patients
The majority of physicians—79 percent—recommend supplements to their patients. The Council for Responsible Nutrition (CRN) has released the survey results with a breakdown included.
- Survey Reveals Top Five Reasons Physicians Recommend Dietary Supplements to Their Patients
The majority of physicians—79 percent—recommend supplements to their patients. The Council for Responsible Nutrition (CRN) has released the survey results with a breakdown included.
- Survey Reveals Top Five Reasons Physicians Recommend Dietary Supplements to Their Patients
The majority of physicians—79 percent—recommend supplements to their patients. The Council for Responsible Nutrition (CRN) has released the survey results with a breakdown included.
- Survey Reveals Top Five Reasons Physicians Recommend Dietary Supplements to Their Patients
The majority of physicians—79 percent—recommend supplements to their patients. The Council for Responsible Nutrition (CRN) has released the survey results with a breakdown included.
- Colds And Flu Cut by 1/3 in Four-City Trial of COLD-FX®
CV Technologies Inc., has announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot’s effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX.
- Colds And Flu Cut by 1/3 in Four-City Trial of COLD-FX®
CV Technologies Inc., has announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot’s effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX.
- Colds And Flu Cut by 1/3 in Four-City Trial of COLD-FX®
CV Technologies Inc., has announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot’s effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX.
- Colds And Flu Cut by 1/3 in Four-City Trial of COLD-FX®
CV Technologies Inc., has announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot’s effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX.
- Colds And Flu Cut by 1/3 in Four-City Trial of COLD-FX®
CV Technologies Inc., has announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot’s effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX.
- Colds And Flu Cut by 1/3 in Four-City Trial of COLD-FX®
CV Technologies Inc., has announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot’s effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX.
- Colds And Flu Cut by 1/3 in Four-City Trial of COLD-FX®
CV Technologies Inc., has announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot’s effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX.
- Colds And Flu Cut by 1/3 in Four-City Trial of COLD-FX®
CV Technologies Inc., has announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot’s effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Increasingly popular omega-3 fatty acids—found in sources like fish—and plant extracts known as phytosterols—which occur naturally in sources like vegetable oils, whole grains, nuts, and legumes—are known to have beneficial effects on fats (lipids) in the blood that affect heart health, such as cholesterol and triglycerides. Now a new study suggests that when taken in combination, they may have even more powerful effects.
Lowering LDL (“bad”) cholesterol and raising HDL (“good”) cholesterol are important steps toward reducing health risks. High total and LDL cholesterol and high triglycerides are associated with an increased cardiovascular disease risk. On the other hand, a high level of HDL cholesterol protects against cardiovascular disease. Lifestyle changes and medication can improve a person’s lipid profile and reduce risks. Researchers are finding that using phytosterols and omega-3 fatty acids may be another way to help lower cholesterol.
Even better together
Phytosterols may have beneficial effects on health including cholesterol reduction. Fish oil, which contains omega-3 fatty acids, is also known to increase HDL cholesterol levels and lower triglycerides. The authors of the current study investigated whether or not using phytosterols in combination with omega-3 fatty acids might have even greater effect on lowering lipids.
For three weeks, 60 people between ages 35 and 70 ate their regular diets and were randomly assigned to receive one of the following: placebo (sunflower oil) capsules alone or in combination with a spread containing 2 grams per day of phytosterols, or capsules containing 1.4 grams per day of omega-3 fatty acids (EPA and DHA) alone or in combination with 25 grams per day of the phytosterol enriched spread.
The combination of omega-3 fatty acids and phytosterols reduced total cholesterol by 13.3% and LDL cholesterol by 12.5%. HDL cholesterol increased by 7.1% in the group receiving omega-3s alone and by 8.6% in the combination group. Triglycerides were also lowered in the omega-3s group by 22.3% and in the combination group by 25.9%.
Tips to lower cholesterol
Here are a few tips for aiming for heart-healthy lipid levels:
• Eat a low-fat, low-cholesterol diet.
• Maintain a healthy weight.
• Exercise regularly.
• A glass of red wine at dinner may help raise “good” cholesterol.
Sometimes lifestyle changes alone are not enough to help improve lipid levels and medication is necessary. This is particularly true for people with other risk factors for heart disease such as diabetes or high blood pressure. If you have high cholesterol see a doctor to find out what steps you should take in order to lower your risk of cardiovascular disease.
Jane Hart, MD |